Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Genetic Alteration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT02298166
What this trial is testing

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations

Who this might be right for
Acute Myeloid Leukemia
University of Ulm 9
Testing effectiveness (Phase 2)UnknownNCT02407366
What this trial is testing

Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
People's Hospital of Guangxi Zhuang Autonomous Region 80
Not applicableLooking for participantsNCT05805202
What this trial is testing

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

Who this might be right for
Atypical Hemolytic Uremic Syndrome
Mario Negri Institute for Pharmacological Research 112
Large-scale testing (Phase 3)Active Not RecruitingNCT04768972
What this trial is testing

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Who this might be right for
Amyotrophic Lateral Sclerosis
Ionis Pharmaceuticals, Inc. 89
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Not applicableStudy completedNCT04560270
What this trial is testing

CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer

Who this might be right for
Pancreatic CancerCirculating Tumor DNAKRAS Mutation-Related Tumors
Poitiers University Hospital 69
Testing effectiveness (Phase 2)UnknownNCT01131429
What this trial is testing

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Neoplasms, LungCarcinoma, Non-Small Cell LungDrug Therapy+1 more
Chinese PLA General Hospital 60
Not applicableLooking for participantsNCT06357845
What this trial is testing

Linking Somatic Mutation Rate With Baseline Exposure in East Palestine

Who this might be right for
Somatic Mutation
Case Comprehensive Cancer Center 500
Testing effectiveness (Phase 2)Study completedNCT01854294
What this trial is testing

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

Who this might be right for
Amyotrophic Lateral Sclerosis
Genervon Biopharmaceuticals, LLC 12
Early research (Phase 1)Study completedNCT01636622
What this trial is testing

Study of Vemurafenib, Carboplatin, and Paclitaxel

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 21
Early research (Phase 1)Active Not RecruitingNCT07038369
What this trial is testing

ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Who this might be right for
Advanced Solid TumorsBreast CancerBreast Carcinoma+24 more
Atavistik Bio, Inc 134
Testing effectiveness (Phase 2)Looking for participantsNCT05536505
What this trial is testing

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

Who this might be right for
MRD
Guangdong Association of Clinical Trials 180
Testing effectiveness (Phase 2)Ended earlyNCT04030429
What this trial is testing

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Who this might be right for
Endometrial Cancer Recurrent
National Cheng-Kung University Hospital 40
Not applicableStudy completedNCT03471572
What this trial is testing

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India

Who this might be right for
Ovarian Cancer
AstraZeneca 240
Testing effectiveness (Phase 2)Study completedNCT03987295
What this trial is testing

Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Who this might be right for
Frontotemporal Dementia
Alector Inc. 33
Testing effectiveness (Phase 2)Study completedNCT04165239
What this trial is testing

The KHENERGYZE Study

Who this might be right for
Mitochondrial DiseasesMitochondrial MyopathiesMitochondrial Encephalomyopathies+2 more
Khondrion BV 27
Not applicableUnknownNCT02156297
What this trial is testing

Sorafenib to Treat FLT3-ITD AML

Who this might be right for
Acute Myeloid LeukemiaFLT3-ITD Mutation
The First Affiliated Hospital of Soochow University 100
Early research (Phase 1)Study completedNCT01613950
What this trial is testing

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07414290
What this trial is testing

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations

Who this might be right for
Parkinson Disease (PD)
Shanghai Vitalgen BioPharma Co., Ltd. 17
Not applicableApproved For MarketingNCT04058210
What this trial is testing

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Next Page